May 29, 2020
1 min read
Save

Top in GI: COVID-19 and IBD, dose optimization in Crohn’s

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

New data from the SECURE-IBD registry suggest that steroids — not anti-TNF therapy — increase the risk for severe COVID-19 among patients with inflammatory bowel disease. It was the top story in gastroenterology last week.

Another top story was about a testing strategy that helped identify patients with Crohn’s disease who would benefit from dose escalation.

Read these and more top stories in gastroenterology below:

Q&A: Steroids increase risk for severe COVID-19 infection in IBD

For patients with inflammatory bowel disease (IBD), risk factors associated with severe COVID-19 infection included increasing age, comorbidities and corticosteroid use, according to an initial analysis of a large, international registry. Read more.

Combination testing may identify who benefits from dose optimization in Crohn’s

Among patients with Crohn’s disease, combination testing of the endoscopic healing index and anti-tumor necrosis factor concentration may identify patients who benefit from dose escalation, according to data from Digestive Disease Week. Read more.

Woman with stomach pain 
Digestive symptoms were common in patients with COVID-19, according to research in the American Journal of Gastroenterology.
Source: Adobe Stock

Diarrhea may be common symptom in patients with COVID-19

Digestive symptoms were common in patients with COVID-19, according to research in the American Journal of Gastroenterology. Patients with these symptoms had a longer time from onset to admission and their prognosis was worse compared with patients without symptoms. Read more.

VIDEO: Steroid use, loss of response prevalent in IBD care

In this exclusive video, Anita Afzali, MD, from The Ohio State University Wexner Medical Center, reviews data that she presented for Digestive Disease Week from a survey that assessed patient and provider perspectives on the management of IBD. Read more.

Stelara linked with better outcomes in Crohn’s

Treatment with Stelara (ustekinumab, Janssen) was associated with superior outcomes in patients with Crohn’s disease who previously failed anti-TNF therapy, according to new study results. Read more.